伦敦：葛兰素史克（GSK）周二（10月27日）表示，预计明年其处于临床试验阶段的癌症药物数量将几乎翻倍，包括处于早期研究阶段的药物，因为该公司正试图重建其肿瘤学业务。
LONDON: GSK said on Tuesday (Oct 27) that it expects to almost double the number of cancer medicines it has in clinical trials next year, including those in early-stage studies, as it tries to rebuild its oncology business.
葛兰素史克肿瘤学研发负责人赫沙姆·阿卜杜拉（Hesham Abdullah）周二早些时候对《华尔街日报》表示，这家药企目前拥有约15款处于临床阶段的在研资产，到2027年这一数字很可能会“接近翻倍”。
The drugmaker's clinical-stage portfolio of about 15 assets would likely "come close to doubling" in 2027, Hesham Abdullah, who heads GSK's oncology research and development, told the Wall Street Journal earlier on Tuesday.
在首席执行官卢克·米尔斯（Luke Miels）的领导下，这家英国药企在癌症药物上押下重注，其中包括今年早些时候以106亿美元收购美国生物技术公司Nuvalent。在此过程中收购的药物之一已于7月获批，另一款药物的监管决定预计将于11月前做出。
The British drugmaker has bet big on cancer drugs under CEO Luke Miels, including its US$10.6 billion takeover of US biotech Nuvalent earlier this year. One of the drugs acquired in the process received approval in July while a regulatory decision on another is expected by November.
米尔斯面临的任务是让投资者放心，公司能够应对其畅销艾滋病药物即将到来的专利悬崖。
Miels faces the task of reassuring investors that the company can navigate looming patent cliffs for its blockbuster HIV drugs.
葛兰素史克肿瘤学产品开发负责人埃里克·理查兹（Eric Richards）本周早些时候在一次医学会议上对路透社表示：“到2027年，我们可能会有近20项III期临床试验在进行中。”
"We may have close to 20 phase threes ongoing in 2027," Eric Richards, who heads oncology product development at GSK, told Reuters earlier in the week at a medical meeting.
Ris-rez和Mo-rez等癌症药物是葛兰素史克雄心的核心。周一，葛兰素史克与恒瑞（Hansoh）联合发布的Ris-rez数据显示，该药帮助难治性癌症患者在疾病未恶化的情况下生存得更久。
Cancer drugs such as ris-rez and mo-rez are at the centre of GSK's ambitions. On Monday, data from GSK and Hansoh's ris-rez showed that it helped patients with a hard-to-treat cancer live longer without the disease worsening.
目前有五项Mo-rez的晚期研究正在进行中，Ris-rez计划的四项晚期试验中也有两项正在进行。
Five late-stage studies for mo-rez are ongoing as are two of four planned late-stage trials for ris-rez.
今年上半年，癌症药物为葛兰素史克贡献了10.8亿英镑（约14.4亿美元）的销售额。该公司将于周三发布第三季度财报。
Cancer drugs contributed £1.08 billion (US$1.44 billion) to GSK's first-half sales. The company is due to report third-quarter earnings on Wednesday.